<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970696</url>
  </required_header>
  <id_info>
    <org_study_id>International OTST Registry</org_study_id>
    <nct_id>NCT01970696</nct_id>
  </id_info>
  <brief_title>International Ovarian &amp; Testicular Stromal Tumor Registry</brief_title>
  <acronym>OTST</acronym>
  <official_title>International Ovarian &amp; Testicular Stromal Tumor Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospitals and Clinics of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Dortmund Wirbelsäulenchirurgie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ResourcePath, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospitals and Clinics of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer&#xD;
      research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood, have&#xD;
      recently been found to be associated with a lung cancer of early childhood called&#xD;
      pleuropulmonary blastoma (PPB). The cause of these ovarian tumors is unknown. DICER1&#xD;
      mutations are seen in the majority of children with PPB. Research shows DICER1 mutations are&#xD;
      also seen in some patients with ovarian tumors. Like PPB, ovarian stromal tumors are highly&#xD;
      curable when found in early stage; however, later forms of the disease are aggressive and&#xD;
      often fatal. The International Ovarian Stromal Tumor Registry collects clinical and biologic&#xD;
      data to understand why these tumors occur and how to treat them. Current work involves the&#xD;
      study of the role of DICER1 and miRNA expression in ovarian stromal tumors. Understanding the&#xD;
      clinical history, predisposing factors and DICER1 and miRNA expression in these ovarian&#xD;
      tumors of childhood will lead to targeted screening and risk stratification for&#xD;
      evidence-based treatment and biologically rational therapies. These efforts will improve the&#xD;
      lives of children by increasing survival and reducing late effects.&#xD;
&#xD;
      The specific goals of the International Ovarian and Testicular Stromal Tumor Registry are:&#xD;
&#xD;
        1. to understand risk factors by studying age, pathologic subtype, histopathologic&#xD;
           features, tumor invasiveness, degree of differentiation, presence of metastasis&#xD;
&#xD;
        2. to collect information on personal and family history in order to refine the clinical&#xD;
           characteristics of patients and families with and without germline DICER1 mutations and&#xD;
           other genetic predisposing factors&#xD;
&#xD;
        3. to determine whether there is a pattern of gene expression or DNA alterations that&#xD;
           correlate with predisposition to ovarian tumors, biologic behavior and clinical outcome&#xD;
&#xD;
        4. to determine optimal screening regimens&#xD;
&#xD;
        5. to use clinical data obtained through the Registry to refine treatment algorithms&#xD;
&#xD;
        6. to establish a collection of annotated biology specimens (tumor tissue and germline DNA)&#xD;
           for future research&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Registry collects and analyzes case-by-case data on ovarian stromal tumors. Cases are&#xD;
      identified:&#xD;
&#xD;
        1. by referrals from clinicians or pathologists&#xD;
&#xD;
        2. by families initiating contact with the Registry&#xD;
&#xD;
        3. by Registry requests to authors of published cases to share further details&#xD;
&#xD;
      The data collected include:&#xD;
&#xD;
        1. clinical and laboratory findings&#xD;
&#xD;
        2. family history&#xD;
&#xD;
        3. imaging studies&#xD;
&#xD;
        4. surgery records&#xD;
&#xD;
        5. pathology records including review and study of pathology materials&#xD;
&#xD;
        6. treatment (surgery, chemotherapy, radiation)&#xD;
&#xD;
        7. recurrences or metastases&#xD;
&#xD;
        8. long-term follow-up&#xD;
&#xD;
      The demographic and clinical data are abstracted into a database secured by password&#xD;
      protection. Each record in the database has a unique Registry number.&#xD;
&#xD;
      Enrollment in the OTST Registry is based on local diagnosis, but central pathology review is&#xD;
      offered as a part of Registry procedures.&#xD;
&#xD;
      For each patient enrolled, the Registry will request 1) whole blood for DNA extraction and&#xD;
      lymphoblastoid cell line generation 2) slides or snap frozen tumor tissue (if available), and&#xD;
      3) paraffin blocks. In some cases, saliva samples, buccal swabs or urine samples will be&#xD;
      obtained for DNA extraction.&#xD;
&#xD;
      Pathology materials are centrally reviewed when available. Any discrepancies in the&#xD;
      diagnostic interpretation are discussed with the submitting pathologist or clinician. When&#xD;
      the central review pathologist cannot confirm diagnosis of a stromal tumor, the referring&#xD;
      physician is notified. The local pathologist retains responsibility for the final&#xD;
      pathological diagnosis. It is the responsibility of the referring physician to notify the&#xD;
      patient regarding any discrepancy found.&#xD;
&#xD;
      Biologic specimens will be banked and stored for future research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2011</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>DICER1 mutations in ovarian and testicular stromal tumors</measure>
    <time_frame>3 years</time_frame>
    <description>We will analyze germline DNA from patients with gonadal stromal tumors to determine the presence of DICER1 mutations. The tumor tissue will also be sequenced. mRNA and miRNA expression will be analyzed on tumor tissue. Results of the above will be correlated with clinical outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical factors associated with outcome in ovarian and testicular stromal tumors</measure>
    <time_frame>3 years</time_frame>
    <description>We will analyze the clinical records to determine which factors influence prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic and Genetic Correlations</measure>
    <time_frame>3 years</time_frame>
    <description>We will correlate the pathologic and genetic data with clinical data to describe factors associated with poor prognosis.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Stromal Tumor</condition>
  <condition>Testicular Stromal Tumors</condition>
  <condition>Ovarian Small Cell Carcinoma</condition>
  <condition>DICER1 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Ovarian Stromal Tumors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Testicular Stromal Tumors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovarian Small Cell Carcinoma</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1) whole blood for DNA extraction and lymphoblastoid cell line generation, 2) stained and&#xD;
      unstained slides and snap frozen tumor tissue (if available), and 3) paraffin blocks.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospectively or retrospectively diagnosed patients with ovarian or testicular stromal&#xD;
        tumors or ovarian small cell carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous or current diagnosis of an ovarian sex cord stromal including but not limited&#xD;
             to: Sertoli-Leydig cell tumor, gynandroblastoma, juvenile granulosa cell tumor,&#xD;
             Sertoli cell tumor, sex cord stromal tumor with annular tubules or undifferentiated&#xD;
             stromal tumor&#xD;
&#xD;
          -  Previous or current diagnosis of a testicular stromal tumor including but not limited&#xD;
             to: juvenile granulosa cell tumor, Sertoli cell tumor, Leydig cell tumor or&#xD;
             undifferentiated stromal tumor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to provide informed consent/assent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris Ann P Schultz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Harris, MPH</last_name>
    <phone>612-813-5861</phone>
    <email>anne.harris@childrensmn.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Ann P Schultz, MD, MS</last_name>
      <phone>612-813-5940</phone>
      <email>OTST@childrensMN.org</email>
    </contact>
    <contact_backup>
      <last_name>Anne K Harris</last_name>
      <phone>612-813-5861</phone>
      <email>OTST@childrensMN.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kris Ann P Schultz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.OTSTregistry.org</url>
    <description>International OTST Registry official website</description>
  </link>
  <link>
    <url>http://www.PPBregistry.org</url>
    <description>International PPB/DICER1 Registry</description>
  </link>
  <reference>
    <citation>Schultz KA, Schneider DT, Pashankar F, Ross J, Frazier L. Management of ovarian and testicular sex cord-stromal tumors in children and adolescents. J Pediatr Hematol Oncol. 2012 May;34 Suppl 2:S55-63. doi: 10.1097/MPH.0b013e31824e3867. Review.</citation>
    <PMID>22525408</PMID>
  </reference>
  <reference>
    <citation>Schultz KA, Sencer SF, Messinger Y, Neglia JP, Steiner ME. Pediatric ovarian tumors: a review of 67 cases. Pediatr Blood Cancer. 2005 Feb;44(2):167-73.</citation>
    <PMID>15490488</PMID>
  </reference>
  <reference>
    <citation>Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clin Obstet Gynecol. 2006 Sep;49(3):464-79. Review.</citation>
    <PMID>16885654</PMID>
  </reference>
  <reference>
    <citation>Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O'Brien PK, Serfas K, Broderick P, Houlston RS, Lesueur F, Bonora E, Muljo S, Schimke RN, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest JR, Nguyen VH, Harach HR, Livingston DM, Foulkes WD, Tischkowitz M. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA. 2011 Jan 5;305(1):68-77. doi: 10.1001/jama.2010.1910.</citation>
    <PMID>21205968</PMID>
  </reference>
  <reference>
    <citation>Schultz KAP, Stewart DR, Kamihara J, Bauer AJ, Merideth MA, Stratton P, Huryn LA, Harris AK, Doros L, Field A, Carr AG, Dehner LP, Messinger Y, Hill DA. DICER1 Tumor Predisposition. 2014 Apr 24 [updated 2020 Apr 30]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from http://www.ncbi.nlm.nih.gov/books/NBK196157/</citation>
    <PMID>24761742</PMID>
  </reference>
  <reference>
    <citation>Pappo AS, Furman WL, Schultz KA, Ferrari A, Helman L, Krailo MD. Rare Tumors in Children: Progress Through Collaboration. J Clin Oncol. 2015 Sep 20;33(27):3047-54. doi: 10.1200/JCO.2014.59.3632. Epub 2015 Aug 24. Review.</citation>
    <PMID>26304909</PMID>
  </reference>
  <reference>
    <citation>Pashankar F, Bisogno G, Ribeiro R, Messinger Y, Schultz KA, Rodriguez-Galindo C. The role of registries and tumor banking in rare pediatric tumors. Curr Pediatr Rep 2015:1-9. Avail online 15 Mar 2015. DOI 10.1007/s40124-015-0077-9.</citation>
  </reference>
  <reference>
    <citation>Schultz KAP and Miller R. (2014) Adnexal Masses in Infancy and Childhood. Coomarasamy A, Davuka W, Shafi M, Chan C (eds): Gynecology and Obstetric Surgery: Challenges and Management Options. Wiley-Blackwell. [BOOK.] [In press; avail may 2015].</citation>
  </reference>
  <reference>
    <citation>Schultz KAP, Frazier L, Schneider DT. (2014) Ovarian and Testicular Sex Cord Stromal Tumors. Frazier, AL, Amatruda JF (eds): Textbook Pediatric Germ Cell Tumors, Pediatric Oncology 1. Berlin Heidelberg. Springer-Verlag. [BOOK.].</citation>
  </reference>
  <reference>
    <citation>Schneider DT, Orbach D, Ben-Ami T, Bien E, Bisogno G, Brecht IB, Cecchetto G, Ferrari A, Godzinski J, Janic D, Lopez Almaraz R, Pourtsidis A, Roganovic J, Schultz KAP, Stachowicz-Stencel T, Fresneau B. Consensus recommendations from the EXPeRT/PARTNER groups for the diagnosis and therapy of sex cord stromal tumors in children and adolescents. Pediatr Blood Cancer. 2021 Jun;68 Suppl 4:e29017. doi: 10.1002/pbc.29017. Epub 2021 Mar 24.</citation>
    <PMID>33760357</PMID>
  </reference>
  <results_reference>
    <citation>Doros L, Yang J, Dehner L, Rossi CT, Skiver K, Jarzembowski JA, Messinger Y, Schultz KA, Williams G, André N, Hill DA. DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome. Pediatr Blood Cancer. 2012 Sep;59(3):558-60. doi: 10.1002/pbc.24020. Epub 2011 Dec 16.</citation>
    <PMID>22180160</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KA, Pacheco MC, Yang J, Williams GM, Messinger Y, Hill DA, Dehner LP, Priest JR. Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol. 2011 Aug;122(2):246-50. doi: 10.1016/j.ygyno.2011.03.024. Epub 2011 Apr 17.</citation>
    <PMID>21501861</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KA, Harris A, Williams GM, Baldinger S, Doros L, Valusek P, Frazier AL, Dehner LP, Messinger Y, Hill DA. Judicious DICER1 testing and surveillance imaging facilitates early diagnosis and cure of pleuropulmonary blastoma. Pediatr Blood Cancer. 2014 Sep;61(9):1695-7. doi: 10.1002/pbc.25092. Epub 2014 May 13.</citation>
    <PMID>24821309</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KA, Harris A, Messinger Y, Sencer S, Baldinger S, Dehner LP, Hill DA. Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry. Fam Cancer. 2016 Jan;15(1):105-10. doi: 10.1007/s10689-015-9831-y.</citation>
    <PMID>26289771</PMID>
  </results_reference>
  <results_reference>
    <citation>Rutter MM, Jha P, Schultz KA, Sheil A, Harris AK, Bauer AJ, Field AL, Geller J, Hill DA. DICER1 Mutations and Differentiated Thyroid Carcinoma: Evidence of a Direct Association. J Clin Endocrinol Metab. 2016 Jan;101(1):1-5. doi: 10.1210/jc.2015-2169. Epub 2015 Nov 10.</citation>
    <PMID>26555935</PMID>
  </results_reference>
  <results_reference>
    <citation>Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors in Pediatric and Adolescent Patients With Clinical Stage I Testicular Stromal Tumors. J Pediatr Hematol Oncol. 2015 Nov;37(8):e441-6. doi: 10.1097/MPH.0000000000000445. Review.</citation>
    <PMID>26479987</PMID>
  </results_reference>
  <results_reference>
    <citation>Golmard L, Vasta LM, Duflos V, Corsini C, Dubois d'Enghien C, McMaster ML, Harney LA, Carr AG, Ling A, Dijoud F, Gauthier A, Miettinen M, Cost NG, Gauthier-Villars M, Orbach D, Irtan S, Haouy S, Schultz KA, Stoppa-Lyonnet D, Coupier I, Stewart DR, Sirvent N. Testicular Sertoli cell tumour and potentially testicular Leydig cell tumour are features of DICER1 syndrome. J Med Genet. 2021 Mar 29. pii: jmedgenet-2020-107434. doi: 10.1136/jmedgenet-2020-107434. [Epub ahead of print]</citation>
    <PMID>33782093</PMID>
  </results_reference>
  <results_reference>
    <citation>Kebudi R, Dural O, Bay SB, Gorgun O, Onder S, Bilgic B, Yilmaz I, Iribas A, Arndt CA, Harris AK, Field A, Schultz KAP, Hill DA. Childhood Rhabdomyosarcoma of the Female Genital Tract: Association with Pathogenic DICER1 Variation, Clinicopathological Features, and Outcomes. J Pediatr Adolesc Gynecol. 2021 Aug;34(4):449-453. doi: 10.1016/j.jpag.2021.01.011. Epub 2021 Jan 20.</citation>
    <PMID>33484847</PMID>
  </results_reference>
  <results_reference>
    <citation>Schneider KW, Cost NG, Schultz KAP, Svihovec S, Suttman A. Germline predisposition to genitourinary rhabdomyosarcoma. Transl Androl Urol. 2020 Oct;9(5):2430-2440. doi: 10.21037/tau-20-76. Review.</citation>
    <PMID>33209717</PMID>
  </results_reference>
  <results_reference>
    <citation>Vasta LM, McMaster ML, Harney LA, Ling A, Kim J, Harris AK, Carr AG, Damrauer SM, Rader DJ, Kember RL, Kanetsky PA, Nathanson KL, Pyle LC, Greene MH, Schultz KA, Stewart DR; Regeneron Genetics Center (RGC) Research Team. Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors. Cancer Genet. 2020 Oct;248-249:49-56. doi: 10.1016/j.cancergen.2020.10.002. Epub 2020 Oct 24.</citation>
    <PMID>33158809</PMID>
  </results_reference>
  <results_reference>
    <citation>Dural O, Kebudi R, Yavuz E, Yilmaz I, Buyukkapu Bay S, Schultz KAP, Hill DA. DICER1-Related Embryonal Rhabdomyosarcoma of the Uterine Corpus in a Prepubertal Girl. J Pediatr Adolesc Gynecol. 2020 Apr;33(2):173-176. doi: 10.1016/j.jpag.2019.12.002. Epub 2019 Dec 12.</citation>
    <PMID>31838154</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KAP, Harris AK, Finch M, Dehner LP, Brown JB, Gershenson DM, Young RH, Field A, Yu W, Turner J, Cost NG, Schneider DT, Stewart DR, Frazier AL, Messinger Y, Hill DA. DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. Gynecol Oncol. 2017 Dec;147(3):521-527. doi: 10.1016/j.ygyno.2017.09.034. Epub 2017 Oct 14.</citation>
    <PMID>29037807</PMID>
  </results_reference>
  <results_reference>
    <citation>Merideth MA, Harney LA, Vyas N, Bachi A, Carr AG, Hill DA, Dehner LP, Schultz KAP, Stewart DR, Stratton P. Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1. Gynecol Oncol. 2020 Mar;156(3):647-653. doi: 10.1016/j.ygyno.2019.12.037. Epub 2020 Jan 15.</citation>
    <PMID>31952842</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KA, Harris AK, Schneider DT, Young RH, Brown J, Gershenson DM, Dehner LP, Hill DA, Messinger YH, Frazier AL. Ovarian Sex Cord-Stromal Tumors. J Oncol Pract. 2016 Oct;12(10):940-946.</citation>
    <PMID>27858560</PMID>
  </results_reference>
  <results_reference>
    <citation>Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors. Urology. 2016 Nov;97:138-144. doi: 10.1016/j.urology.2016.06.066. Epub 2016 Aug 15. Review.</citation>
    <PMID>27538802</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospitals and Clinics of Minnesota</investigator_affiliation>
    <investigator_full_name>Kris Ann Schultz</investigator_full_name>
    <investigator_title>Kris Ann P. Schultz, MD, MS</investigator_title>
  </responsible_party>
  <keyword>ovarian</keyword>
  <keyword>testicular</keyword>
  <keyword>stromal</keyword>
  <keyword>Sertoli</keyword>
  <keyword>Leydig</keyword>
  <keyword>gynandroblastoma</keyword>
  <keyword>juvenile granulosa cell tumor</keyword>
  <keyword>DICER1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

